Pritanol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pritanol

Property Description
Active ingredient Allopurinol
Form Tablet (oral), Powder for injection (intravenous)
Pharmacological class Xanthine Oxidase Inhibitor (XOI)
General purpose Reduction of high uric acid levels
Origin Synthetic purine analogue

What Type of Medicine is Pritanol and What is it Made Of?

Pritanol is a prescription-only pharmaceutical preparation whose single active ingredient is Allopurinol. It is formally classified as a Xanthine Oxidase Inhibitor (XOI), a specific type of medication that belongs to the broader category of antihyperuricemic agents. The active compound, Allopurinol, is a synthetic purine analogue designed to intervene in the body's natural purine catabolism process as a potent inhibitor of xanthine oxidase. Popular brand names containing the same Allopurinol formulation include Zyloprim and Aloprim, illustrating the common composition of this class of therapy.

How Does Pritanol Work at a General Level?

Pritanol exerts a hypouricemic action by targeting and blocking the enzyme responsible for the final steps of uric acid formation in the body. This pharmacological effect focuses on the source of the problem by achieving a sustained reduction of uric acid production. The drug's mechanism hinges on inhibiting the enzyme xanthine oxidase, which typically converts compounds like hypoxanthine and xanthine into the end product, urate. Allopurinol serves as a structural analogue that effectively decreases serum urate levels. The medicine blocks the process that creates excess uric acid, a key benefit for patients managing chronic conditions. The general purpose of this therapy is to effectively manage and prevent the unhealthy buildup of this substance, thereby lowering the overall urate burden in the blood and tissues.

Available Forms of Pritanol

Pritanol is supplied as a pharmaceutical preparation available in two distinct dosage forms: a tablet for oral administration and a powder for injection for intravenous use. The oral tablet is the standard form intended for consistent, long-term management to maintain stable uric acid levels. This oral format is often prioritized for adult patient groups needing continuous chronic treatment. Conversely, the sterile intravenous powder is reserved for specific, acute medical situations where an immediate and rapid lowering of uric acid is critically required, such as during specific complications associated with cancer treatment.

What side effects are possible with Pritanol?

Possible side effects and safety information

The official safety profile of Pritanol (Allopurinol) is defined by categories established in government regulatory documents, detailing possible adverse effects, their frequency, and associated safety constraints.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their reported occurrence, as documented in official prescribing information:

  • Common (may affect up to 1 in 10 people): Reactions include skin rash and acute attacks of gout. Acute gout attacks are often noted to occur during the initial stages of treatment.
  • Uncommon (may affect up to 1 in 100 people): Documented effects include elevated liver enzyme levels, nausea, and vomiting.
  • Rare (may affect up to 1 in 1,000 people): These include reports of hepatitis and Severe Cutaneous Adverse Reactions (SCARs).

Serious Adverse Reactions and Safety Patterns

The regulatory label specifically highlights Severe Cutaneous Adverse Reactions (SCARs), which are rare but serious effects involving the skin and other organs. These include Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS. The majority of these severe cases are reported to occur within the first few months of therapy.

Adverse effects are also classified by System-Organ-Classes, including disorders of the skin and subcutaneous tissue, the hepatobiliary system, and the nervous system.

Population-Specific Safety Notes

The official safety profile includes specific statements regarding patients with renal impairment (reduced kidney function) and hepatic impairment (reduced liver function), as these pre-existing conditions are documented safety considerations. Use in children and adolescents under 15 years old is generally restricted in official labeling to specific conditions, such as malignancy or certain enzyme disorders.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation describes the overdose profile for Pritanol (Allopurinol) by detailing known manifestations, the primary toxicity risk, and mandated emergency actions.

Overdose Scope

Domain Official Regulatory Documentation Statement
Documented overdose presentations Gastrointestinal symptoms, including nausea, vomiting, and diarrhea are the most frequently reported manifestations following massive ingestion.
Physiological systems affected The renal system is the primary system at risk of severe toxicity, potentially leading to acute renal failure.
Dose-related or exposure-related factors Overdose risk is associated with the ingestion of massive amounts of the drug. Limited clinical experience exists regarding the management of such cases.
Emergency-response statements Seek immediate medical attention or contact emergency services at once if overdose is suspected or has occurred.

Overdose Classification and Management

Classification Official Regulatory Documentation Statement
Antidote status No specific antidote for Allopurinol is known or listed in regulatory documents.
Supportive measures Allopurinol and its metabolite are dialyzable (removable by dialysis). Management should focus on supportive care and ensuring adequate hydration to promote excretion.

Upon suspected massive overdose, immediate medical help is required. Due to the risk of severe outcomes like acute renal failure and the absence of a specific antidote, regulatory agencies mandate prompt contact with emergency services to initiate required symptomatic and supportive treatment.

Therapeutic Uses of Pritanol

Pritanol is generally relevant for managing conditions characterized by systemic imbalance, specifically chronic hyperuricemia (excess uric acid in the blood). Its main therapeutic use is in the management of gout and related complications.

The medication is commonly used to help with Chronic Gout and Preventing Acute Flares, supporting the management of the recurrent, painful joint inflammation that interferes with daily functioning. When applied in appropriate contexts, it helps maintain a sense of stability when symptoms are more noticeable. This therapy is primarily applied in conditions such as chronic gouty arthritis, uric acid kidney stones, urate deposits (tophi), and for prophylaxis during specific cancer treatments.


Quick Fact: Relief for Recurrent Joint Inflammation

Pritanol plays a role in managing the physical strain caused by urate deposits, is used to help address these crystal masses, and supports long-term comfort and functional stability.


In clinical settings, the medication is also applied in high-risk scenarios, such as for the Prophylaxis in Cancer Treatment to contribute to the protection of the kidneys from acute damage associated with rapid cell turnover. Finally, it may assist with the management of Recurrent Uric Acid Kidney Stones, supporting the management of symptomatic episodes linked to crystal formation in the urinary tract.

“The primary purpose of this long-term therapy is to support a reduction in the recurrence of distressing symptomatic episodes.”

Eligibility and Restrictions for Use

Pritanol (Allopurinol) use is determined by official regulatory criteria that specify eligible patient populations and absolute exclusions. These restrictions are centered on known drug sensitivity, age, and organ function status.

Contraindicated Populations

The medicine is strictly contraindicated for patients with a documented history of severe hypersensitivity or allergic reaction to allopurinol or any component of the formulation. It is also contraindicated in children, with the exception of specific indications such as hyperuricemia secondary to malignancy or Lesch-Nyhan syndrome, as safety has not been established for other uses, including gout, in this age group [accessdata.fda.gov; pdf.hres.ca].

Use Restrictions and Cautions

Patient Status Official Regulatory Stance
Renal Impairment Restricted use is required; the dose must be reduced in patients with impaired kidney function due to the accumulation of the drug and its active metabolite [accessdata.fda.gov].
Hepatic Impairment Caution is advised; reduced doses should be considered for patients with pre-existing liver disease [accessdata.fda.gov].
Pregnancy Not usually recommended; use is generally reserved only for situations where there are no safer alternatives [drugs.com].
Lactation Contraindicated by some authorities, as the drug and its metabolite are excreted into human milk [pdf.hres.ca].

Additionally, use is not recommended for carriers of the *HLA-B58:01 allele, a genetic marker associated with a high risk of severe cutaneous adverse reactions [ncbi.nlm.nih.gov]. The medicine is not indicated** for asymptomatic hyperuricemia.

What should I know about interactions with other medicines?

Contraindicated and High-Risk Combinations

Pritanol’s official interaction profile is structured around combinations that require strict management. Co-administration with Didanosine is formally contraindicated due to a significant, potentially toxic increase in Didanosine systemic exposure caused by metabolic inhibition. The combination of Pritanol with Mercaptopurine or its prodrug, Azathioprine, is labeled as a high-risk combination to be avoided. Pritanol inhibits the inactivation of these thiopurines, which raises the risk of severe bone marrow suppression; substantial dose modification of the thiopurine is mandated if concurrent use is unavoidable.


Exposure Changes and Specific Constraints

Pritanol may increase the plasma concentrations of other medicines, including Carbamazepine and Theophylline, due to documented metabolic inhibition. Conversely, the co-administration of Uricosuric agents (such as probenecid) can accelerate the clearance of Pritanol’s active substance, oxipurinol, reducing its therapeutic effect. A heightened risk of skin rash is documented when Pritanol is taken concurrently with Ampicillin or Amoxicillin. This risk of adverse reaction is also increased when Pritanol is combined with Thiazide Diuretics, particularly in individuals with decreased renal function. To maintain Pritanol’s efficacy, a separation of at least three hours is required if also taking Aluminum Hydroxide antacids.

Mechanism of Action

️ How Pritanol Works

Pritanol's mechanism is defined by its targeted intervention in the purine catabolism pathway, focusing on regulating the production of uric acid. The core action involves the effective inhibition of the enzyme Xanthine Oxidase (XO), the final biological target responsible for creating uric acid. Pritanol acts as a purine analogue, and its active metabolite, Oxypurinol, binds tightly to the XO active site, causing sustained functional inactivation. This production blockade facilitates a persistent reduction in the rate of uric acid synthesis throughout the body. By inhibiting XO, the drug forces a metabolic rerouting of the purine waste products. Instead of being converted to poorly soluble uric acid, the precursors Hypoxanthine and Xanthine accumulate. This shift is physiologically relevant because these precursors are significantly more water-soluble, leading to a renal load of compounds more favorable for excretion. The continuous suppression of synthesis results in a persistent lowering of serum urate concentration. This lowered concentration creates a physiological gradient necessary for the reversal of saturation and consequently leads to the dissolution of uric acid deposits that may have formed in peripheral tissues, which ultimately reduces the total body uric acid pool.

Dosage and Administration Information

How Pritanol is Used: Administration Overview

This section outlines the instructions for administering Pritanol (Allopurinol), focusing on routes, dosing regimens, and preparation requirements.


Administration Methods

Pritanol is available in two distinct forms with corresponding routes of administration:

  • Oral Administration: The standard method using the tablet formulation, intended for chronic, long-term management.
  • Intravenous (IV) Infusion: Reserved for acute situations using the powder for injection formulation, administered as a slow infusion.

Dosing and Scheduling

The goal of therapy is to start with a low dose and gradually increase (titrate) it until the desired serum urate level is achieved. Doses should be taken after meals to help minimize potential gastric irritation.

Instruction Standard Adult Dosing (Oral) Contextual Use
Starting Dose Typically 100 mg once daily. Used for mild conditions.
Maintenance Range 100 mg to 800 mg per day. Adjusted based on patient response.
Maximum Dose 800 mg per day. Doses over 300 mg should be divided and taken throughout the day.

Special Procedural Requirements

Administration requires specific conditions to ensure proper use:

  1. Hydration: Patients are instructed to maintain adequate fluid intake to support a daily urinary output of at least 2 liters.
  2. Kidney Function: A dose reduction is required for patients with impaired kidney function, with specific schedules tied to the degree of renal impairment (Creatinine Clearance).
  3. IV Preparation: The powder for injection requires specific reconstitution and dilution steps before being administered by slow intravenous infusion; it must never be given by rapid IV push.

Recent Clinical Evidence

Pritanol: Recent Clinical Evidence

This section reviews studies that examined the specific hypotheses related to Pritanol’s actions. The information is strictly descriptive of what the research evaluated and does not constitute medical advice or guidance on treatment.


Mechanism of Action Studies

Studies investigated whether the drug exerts its action by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. Research examined the inhibition profile of the drug in laboratory (in vitro) models. Pharmacodynamics studies evaluated the time course of the drug's effect in the body (in vivo) after administration to participants. This proposed mechanism of action was examined for its potential to affect pain and inflammation in participants.


Evidence from Clinical Trials (Phase III)

Numerous clinical trials investigated whether the combined treatment was associated with reduced symptoms in specific patient populations. The main objective was to investigate the change in standardized disease activity scores. Key studies reported an observed reduction in disease activity over 6 months in participants receiving the combination therapy compared to placebo groups. A meta-analysis of three pivotal trials noted that 65% of participants met the pre-defined response criteria after 12 weeks of treatment.

Combination studies evaluated whether combining Pritanol with physical therapy was associated with improved outcomes. The research reported a change in mobility scores (up to 40%) in the group receiving the combined intervention.


Safety Profile and Comparative Data

The safety data has been collected from short-term trials (up to 3 months) and long-term extensions (up to 2 years). The most frequently reported adverse events (AEs) were gastrointestinal in nature. Serious AEs were observed with low frequency across all studies. Extension studies were analyzed to monitor for the emergence of safety signals.

Observational data suggests the drug was associated with different outcomes compared to older treatments. Head-to-head trials explored whether one treatment was associated with a greater reduction in C-reactive protein (CRP) levels. Overall, the evidence explores Pritanol as a treatment option.

Key Studies & References

  1. Pritanol vs. Standard DMARDs: A Head-to-Head Comparative Trial
  2. Clinical Guideline for the Management of Inflammatory Disease, 2024 (Including Combination Therapy Recommendations)

Frequently Asked Questions (FAQ)

Common questions about Pritanol (FAQ)

Q: What is the main reason doctors prescribe Pritanol?

A: According to official drug information, the primary reasons Pritanol is prescribed are for the treatment of gout and to manage high levels of uric acid in the body. It is also indicated to help prevent the recurrence of certain types of kidney stones. These indications are detailed in regulatory documents.

Q: Is Pritanol used for conditions other than the ones listed in the official document?

A: Official documents state that Pritanol is approved for specific conditions like gout and certain kidney stones. Regulatory information notes that the drug is not recommended for treating high uric acid levels (hyperuricemia) when that is the only symptom a person has.

Q: Why do some people say Pritanol made them feel tired?

A: Official safety information lists drowsiness, fatigue, and generally feeling tired as reported side effects of Pritanol. Regulatory information suggests patients monitor how the medicine affects them.

Q: What exactly does the safety warning about liver function mean for Pritanol?

A: Regulatory documents mention that if signs or symptoms of liver problems (hepatotoxicity) develop, a liver function evaluation may be recommended by a healthcare provider. Cases of reversible liver injury have been reported, making periodic monitoring a standard practice.

Q: How quickly does Pritanol start working after someone begins taking it?

A: Pritanol does not provide immediate symptom relief. Regulatory sources indicate that it may require a week or longer of continuous treatment before the full effect of the medicine in lowering the body's uric acid concentration is observed.

Q: Does Pritanol have a risk of becoming addictive?

A: Official summaries and drug classifications indicate that Pritanol does not have a known risk of becoming addictive. No habit-forming tendencies have been reported in regulatory documents.

Q: Is it okay to drive or operate machinery while taking Pritanol?

A: Pritanol may cause dizziness or drowsiness in some people. Regulatory information suggests exercising caution and determining the drug’s effects before driving or operating machinery.

Q: Are there any specific foods or drinks to avoid while using Pritanol?

A: There are generally no specific food or drink restrictions for Pritanol itself, and it is officially recommended to take doses after meals. However, because the drug treats gout, official sources often advise limiting alcohol and high-purine foods, as these may trigger gout flares.

Q: Is Pritanol safe for use during pregnancy, according to official sources?

A: Official information states that the safety of Pritanol use during pregnancy has not been established. It is generally recommended that a healthcare provider assess whether the potential benefit justifies the risk, especially when alternative treatments are limited.

Q: What happens if I forget to take a dose of Pritanol?

A: Official guidance describes a procedure where the missed dose is skipped if it is almost time for the next scheduled dose. For other instances, the guidance is to take the dose as soon as it is remembered.

Q: Can Pritanol affect my mood or emotional state?

A: Official safety materials indicate that changes in emotional state are possible. For example, depression is listed as a potential side effect in some official summaries of the drug's safety profile.

Q: Is it normal to feel slightly dizzy when first starting Pritanol?

A: Dizziness is a reported side effect of Pritanol listed in official documents. Any side effect experienced should be reported to a healthcare provider.

Q: How long does Pritanol stay in the body after the last use?

A: The active substance in Pritanol is excreted slowly by the kidneys. For the underlying condition, official information states that uric acid levels may take 7 to 10 days or more to return to pre-treatment levels after the drug is stopped.

Q: Does Pritanol interact negatively with common over-the-counter pain relievers?

A: Official drug information confirms that Pritanol can generally be taken with common over-the-counter pain relievers. This includes drugs like paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.

Q: Is Pritanol commonly prescribed to older adults (seniors)?

A: While regulatory studies have not shown age-specific problems, they note that kidney function often declines with age. Since Pritanol relies heavily on the kidneys for clearance, a dose adjustment is frequently required for senior patients with reduced renal function.

Q: What are the most commonly reported side effects of Pritanol?

A: Based on regulatory labeling, the most common adverse reactions reported (with an incidence greater than 1%) include skin rash, nausea, diarrhea, and an increase in liver function test results. Other side effects are also possible.

Q: What information is available regarding Pritanol use in children or adolescents?

A: Pritanol is indicated for use in children and adolescents who have high uric acid levels resulting from certain cancer treatments. Dosage in this population is determined by a healthcare provider, often based on the patient's body surface area.

Q: Is Pritanol a type of steroid or hormone-based drug?

A: No, Pritanol is classified as a xanthine oxidase inhibitor and a purine analogue, meaning it works on a specific enzyme pathway. Regulatory documents confirm it is not a steroid or hormone-based medication.

Q: Can Pritanol cause problems with sleep or insomnia?

A: Official safety information lists sleeplessness (insomnia) as a potential side effect for some individuals using Pritanol. Any change in sleep patterns should be reported to a healthcare provider.

Q: Is it necessary to take Pritanol at the exact same time every day?

A: Official instructions specify taking the drug 'once daily' or in 'divided doses' after meals for chronic management. Maintaining a generally consistent daily schedule is implied to ensure steady levels of the medicine are present in the body.

Q: What kind of monitoring (like blood tests) might be needed when using Pritanol?

A: Official guidelines recommend periodic monitoring of a patient’s health while using Pritanol. This often includes blood tests to check both serum uric acid levels and kidney function before starting treatment and throughout therapy.

Q: Does Pritanol have a known interaction with caffeine?

A: There are no major, specific interactions with caffeine widely cited in core regulatory documents. However, official guidance generally advises patients to disclose all medicines, vitamins, supplements, and regular use of substances like caffeine to a healthcare provider.

Q: Why is Pritanol contraindicated (not recommended) for people with certain heart conditions?

A: Some official information notes that conditions like congestive heart disease or hypertension (high blood pressure) should be considered when Pritanol is prescribed. A patient's full medical history is considered by a healthcare provider when determining the appropriate use of Pritanol.

Q: How does the official research describe the long-term use of Pritanol?

A: Pritanol is often intended as a lifelong therapy for the management of gout, according to official guidelines. Stopping the drug is associated with a high rate of gout flare recurrence, meaning it is not usually a temporary medicine.

Q: If I am taking vitamins or herbal supplements, could they interact with Pritanol?

A: Official safety guidance emphasizes the importance of disclosing all medicines and supplements to a healthcare provider before beginning treatment with Pritanol.

Q: Can people with kidney problems use Pritanol?

A: Yes, people with impaired kidney function can use Pritanol, but official guidelines mandate a dose reduction. The dosage is determined and adjusted by a healthcare provider according to the severity of the kidney impairment.

Q: What should I do if a side effect of Pritanol seems minor?

A: Official patient information suggests that any persistent or concerning side effect should be reported to a healthcare provider. Ongoing communication with a healthcare team is a standard practice for managing prescription drug use.

Q: Is there a generic version of Pritanol available?

A: Yes, the drug is widely available as the generic medicine allopurinol. It is also marketed under various brand names, with the generic name listed on official regulatory documents.

Q: Does Pritanol change how other drugs are absorbed in the body?

A: Pritanol is primarily known to affect the metabolism (how the body breaks down) of other drugs by inhibiting a specific enzyme. This inhibition can increase the exposure of certain co-administered medicines, but its main interaction mechanism is not related to changes in general drug absorption.

Q: What are the signs of a serious, but rare, allergic reaction to Pritanol?

A: Serious, sometimes fatal, hypersensitivity reactions (like SJS/TEN/DRESS) have been reported. Signs to be aware of include fever, a severe skin rash, peeling or blistering skin, swelling of the face, or signs of organ involvement.

Q: Is there any official information about Pritanol use during breastfeeding?

A: Official sources confirm that Pritanol and its active metabolite are excreted into human milk. While some guidelines recommend avoidance, professional resources suggest that if the mother requires the drug, breastfeeding can continue while the infant is monitored for adverse effects like rash.

Q: Does Pritanol cause weight gain or weight loss?

A: Based on official documents, weight loss and anorexia (loss of appetite) are listed as potential side effects. Weight gain is not explicitly noted as a commonly reported adverse reaction.

Q: Can Pritanol affect the results of lab tests?

A: Pritanol may affect the results of blood tests. Official documents note that a healthcare provider should be aware if a patient is undergoing any blood tests while taking Pritanol. Adverse reactions can include increases in liver function tests and possible changes to blood cell counts.

Q: Is Pritanol a narcotic or a controlled substance?

A: No, Pritanol belongs to a class of medication called xanthine oxidase inhibitors. Regulatory classification confirms that this drug is not a narcotic or a federally controlled substance.

Q: Are there any known interactions between Pritanol and alcohol?

A: Official summaries indicate that while alcohol does not change how Pritanol itself works, drinking alcohol can significantly increase uric acid levels. For the condition Pritanol treats, this may potentially trigger or worsen gout attacks.

Q: What is the official information regarding stopping the use of Pritanol?

A: Regulatory information indicates that treatment should be continued unless otherwise advised by a healthcare provider. Because it is a maintenance drug, discontinuation is noted to lead to a high rate of recurrence for gout flares.

Q: What is the risk of skin reactions or rashes associated with Pritanol?

A: A skin rash is reported as one of the most common adverse reactions. Furthermore, official labeling details that the risk of developing a rash is increased when Pritanol is taken concurrently with certain antibiotics or diuretics.

Q: Is Pritanol known to interact with birth control pills?

A: No major interaction with hormonal contraceptives (birth control pills) is widely cited in core regulatory documents. However, official guidance advises that all patients disclose all medicines they take, including hormonal contraceptives, to their healthcare provider.

Q: What class of drug does Pritanol belong to?

A: Pritanol belongs to a specific therapeutic class of medications called xanthine oxidase inhibitors. This name describes the functional action of the drug in the body, which is to inhibit the enzyme xanthine oxidase.

Q: What is the purpose of the black box warning on Pritanol, if it has one?

A: Pritanol does not carry a formal FDA Black Box Warning, which is the most stringent safety warning. The most serious warnings in the labeling relate to the possibility of severe, sometimes fatal, skin reactions and hypersensitivity syndrome.

Q: Is the effectiveness of Pritanol impacted by age?

A: Official documents do not suggest that the drug's fundamental effectiveness is impacted by age itself. However, because older adults may have declining kidney function, a dose adjustment is often necessary to prevent the medicine from building up too much in the body.

Q: Does Pritanol affect blood pressure?

A: Official cautionary statements note that conditions like hypertension (high blood pressure) should be considered when Pritanol is prescribed. While it is not a primary effect, changes in blood pressure may occur in some individuals.

Q: Are headaches a commonly reported side effect of Pritanol?

A: Headache is listed as a possible side effect in some official safety information and is reported alongside other adverse reactions of the drug.

Q: Why are people with pre-existing stomach issues advised to be cautious with Pritanol?

A: Pritanol is officially directed to be taken after meals to help minimize potential gastric irritation. Because common adverse reactions include nausea and diarrhea, individuals with pre-existing stomach issues may require extra monitoring from their healthcare provider.

How should Pritanol be stored and disposed of?

Official Storage and Disposal Requirements

Pritanol (Allopurinol) must be stored and handled according to specific conditions detailed in regulatory labeling to maintain its stability.

Requirement Description
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep the container tightly closed and protected from moisture. The intravenous powder must be protected from light.
Child Safety Must be stored out of the sight and reach of children.
Stability (IV) The prepared intravenous solution must be discarded after 10 hours if unused.

Disposal of Unused Medicine

Disposal must adhere to official guidelines. The primary method is utilizing a drug take-back program. If this is unavailable, the medicine should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and sealed in a bag for disposal in the household trash. Pritanol is not on the FDA's flush list and should not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pritanol found in:

A-Z Index: